NewsRoom Articles - Page 92 of 154 - PsychedelicNewsWire (PNW)

FridayJul 02, 2021 10:23 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share its Drug Development Pipeline and the Company’s Progress in the Psych Investor Summit

Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and Development The virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDT It will focus on the psychedelics industry, showcasing the latest research and development within the sector Mr. Greg McKee, Chairman and CEO of Tryp Therapeutics, will share information on the company, along with its drug development pipeline In an official statement dated June 24, 2021, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) confirmed that it would participate in the Psych Investor Summit: Research and Development. The virtual event, scheduled on Wednesday,…

ThursdayJul 01, 2021 3:15 pm

Scientists Develop Synthetic Ibogaine Compound That Can Treat Addiction, Depression

Researchers from the University of California-Davis have developed a synthetic version of ibogaine, a psychedelic drug that is nonhallucinogenic. The synthetic compound has the potential to treat various psychiatric disorders, including depression and addiction. The researchers’ findings were reported in the “Nature” journal. David Olson, an assistant professor of chemistry at the institution who was also the senior author of the paper, stated that while psychedelic drugs were powerful substances that affected the brain, it was a shame that very little was known about them. What is known is that ibogaine is extracted from the Tabernanthe iboga plant. Various anecdotal…

WednesdayJun 30, 2021 2:07 pm

XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track

XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule” The program, which started in early 2021, is slated for completion in late Q3 2021 The first initial production batches were completed successfully, marking a significant milestone for the program Mescaline will form a critical component in XPhyto’s psychedelic medicine program and work towards providing a foundation for its drug formulation and clinical validation work XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) recently announced that its Good Manufacturing Practices (“GMP”) mescaline synthesis program in North America is “on schedule” for completion in late Q3 2021…

WednesdayJun 30, 2021 2:00 pm

New Texas Law Mandates Study of Psychedelics’ Effects on Military Vets

Gov. Greg Abbott of Texas recently approved a legislation that makes it compulsory for the state to look into the therapeutic potential of psychedelics. This approval was made only a few days after the governor signed a separate bill to expand the state’s medical cannabis program. Under the psychedelics bill, the state of Texas will be required to conduct research on the medical benefits and risks of ketamine, MDMA and psilocybin for military veterans, in collaboration with a military-focused medical center and the Baylor College of Medicine. The bill also makes it mandatory for a clinical trial on psilocybin for…

WednesdayJun 30, 2021 1:27 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Ships Initial Order of 0.5 Gram Vape Cartridges

Pure Extracts announced initial shipment of 0.5 gram vape cartridges to Alberta Gaming, Liquor & Cannabis CBD vape market has experienced strong growth in recent times, with one market research firm forecasting sector to be worth over $28bn by 2027 Pure Extracts has simultaneously sought to broaden its SKU’s within vape sector, commencing manufacture of larger, 1 gram FSO vape cartridge to better cater to changing customer demand patterns Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, functional mushrooms, and rapidly emerging psychedelic sector, announced that its whole owned subsidiary,…

TuesdayJun 29, 2021 1:30 pm

Mouse Study Uncovers LSD Mechanism That Promotes Positive Social Behavior

A recent study conducted by researchers and one that involved mice, has found a mechanism that may be used to explain the prosocial behavioral effects of LSD microdoses (lysergic acid diethylamide). The study, which was published in the “Proceedings of the National Academy of Sciences” journal, pioneers further research into whether LSD could be efficacious in treating ailments that negatively influence the social behavior of an individual. In the recent past, microdosing has become a popular topic of discussion with regard to whether the method is an effective practice for the consumption of psychedelics. For those who may not be…

MondayJun 28, 2021 1:30 pm

Researchers Find Naturally-Occurring Psychedelic Compound in Rat Brains

In the recent past, individuals from the different parts of the United States. as well as other countries in the world, have been traveling to South America to partake in psychedelic retreats. During these ceremonies, the individuals consume a brewed concoction made from ayahuasca, which has been used traditionally by indigenous communities in sacred religious ceremonies. The psychoactive brew induces hallucinogenic episodes that most of these individuals cite as life-changing. The main active ingredient that causes these psychedelic visions is known as DMT (dimethyltryptamine). A recent study conducted by researchers from the School of Medicine at the University of Michigan…

FridayJun 25, 2021 1:45 pm

Researchers Decry Scant Scientific Data on Psychedelic Microdosing

As psychedelics have become more popular and research has found the numerous benefits these substances potentially hold, microdosing has increased in popularity as well. For those who may not have come across the term, it refers to the practice of consuming low doses of psychedelic substances to improve an individual’s productivity, creativity or mood. While this practice has been heralded by some as effective, scientific evidence to back these claims is yet to be discovered. Now a team of researchers led by the Maastricht University and Imperial College London have investigated the practice and published its findings in the “Journal…

FridayJun 25, 2021 11:43 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Discusses Its Vision for Addressing Patient Needs

In 2021, Tryp Therapeutics plans on expanding its academic collaborations It also plans to initiate Phase 2a clinical studies for its synthetic psilocybin drug product as a way to determine efficacy in patient populations Tryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their dissociative state, mainly through innovations in drug formulation and delivery A primary objective of the administration of psilocybin is to increase the neuroplasticity of the brain Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently shed light on its operations and the vision that it has both…

ThursdayJun 24, 2021 3:18 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments

Decision represents opportunity to help millions suffering from social, generalized anxiety disorders Global markets will reach an estimated $4 billion this year, with significant growth projected looking forward WHO estimates that 1 in 13 adults globally suffer from anxiety; treatment options have slow onset, undesirable side effects Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has identified social anxiety disorder, or SAD, and generalized anxiety disorder, or GAD, as the initial target indications for its proprietary psychedelic molecule CYB004 (https://ibn.fm/BQdjY). Collectively, the two global markets will reach an estimated $4 billion this year, with significant…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000